Corporate News

Alexium (AJX.AX) traded flat during the 24‑hour period ending at 06:07 PM Central Europe on Friday 23 October 2026, with a 0 % change in price. The share is currently quoted at approximately AUD 0.01 on major Australian exchanges. The company’s share supply stands at 3.1 billion, giving it a market capitalisation of roughly AUD 10.7 million. In the last 24 hours, approximately AUD 6.7 thousand worth of Alexium shares were exchanged, a modest volume that reflects the company’s limited liquidity. Since the end of the previous month, the stock has declined by 28.57 %. A 200‑day simple moving average also sits at AUD 0.01, underscoring the flat trajectory. The highest price over the past 52 weeks was AUD 0.01, recorded on 8 September 2026, while the lowest price reached AUD 0.00 on 21 October 2026.

Recent Corporate Developments

Alexium International Group Ltd. has announced a series of milestones across its intranasal therapeutic portfolio. The flagship erectile dysfunction products, SPONTAN and ROXUS, completed a Phase II clinical trial that demonstrated a rapid onset of action—median absorption rates that were six times faster than those of a conventional oral reference drug. Real‑world evidence from a cohort of more than 140 men showed high rates of improved erectile hardness and penetration, particularly among patients who value convenience or who have undergone prostate surgery.

In the United States, the company has launched patient‑specific prescription fulfilment for ROXUS through a partnership with a telehealth platform and an exclusive pharmacy partner. This marks the first commercial launch route for the product in the U.S. market. Additionally, Alexium secured definitive agreements with U.S. partners to broaden distribution of its products, positioning the company for a more robust commercial presence in North America.

Beyond erectile dysfunction, Alexium is advancing OROFLOW, an intranasal spray aimed at treating oesophageal motility disorders. The product has received ethics approval and is awaiting hospital contract sign‑off. The company’s strategy remains focused on expanding its intranasal technology platform while maintaining a solid cash position and zero debt.

Market Context: Peer Performance

The performance of related stocks in the Australian market over the past 24 hours provides a useful backdrop for Alexium’s recent activity:

  • Bsa (BSA.AX) traded flat at AUD 0.19, with a market capitalisation of AUD 12.8 million and a price‑to‑earnings ratio of 4.18.
  • Felix (FLX.AX) also traded flat at AUD 0.03. The company announced on 22 October 2026 that it will request quotation for a new series of ordinary fully paid shares on the ASX, issuing 2.8 million new shares under a previously announced purchase plan. No additional issuances are pending, and the update did not disclose specific pricing.
  • Venari Minerals Nl (VMS.AX) traded flat at AUD 0.11, with a market capitalisation of AUD 12.5 million.
  • Ozaurum (OZM.AX) traded up 1.56 % at AUD 0.06, with a market capitalisation of AUD 12.6 million.
  • Orbit (OBT.AX) traded flat at AUD 0.01, with a market capitalisation of AUD 12.7 million.

Company Overview

Alexium International Group Ltd. is headquartered in Perth, Australia, and operates within the materials sector, focusing on chemicals and related technologies. The company holds the rights—outside the United States—to a line of protective textiles that safeguard against chemical, biological, and radiation threats. In addition, Alexium develops self‑decontaminating paints for military vehicles, further diversifying its product portfolio.

For further details on Alexium’s offerings and corporate updates, visit the company’s website at www.alexiuminternational.com or consult its listings on the ASX All Markets stock exchange.